Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia

Part of paid clinical trials in Buffalo, New York.

Sponsor
Roswell Park Cancer Institute
Study ID
NCT00053144
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
15 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of combining irinotecan with cytarabine in treating patients who have refractory or recurrent acute myeloid leukemia or chronic myelogenous leukemia.

Key Dates

Start date
Nov 30, 1999
Status verified
Mar 2011
Primary completion
Feb 28, 2003
Completion
Mar 31, 2003

Study Design

Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
Roswell Park Cancer InstituteBuffaloNew York14263-0001-

Find similar trials in Buffalo, NY

By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
Roswell Park Cancer Institute· Buffalo, NY

Related Studies